J Neuroimmunol. 2004 Jan; 146(1-2): 153-61
Ciric B, Van Keulen V, Paz Soldan M, Rodriguez M, Pease LR.
Department of Immunology, Mayo Clinic College of Medicine, 200 First
Street SW, 55905, Rochester, MN, USA
A set of antibodies capable of binding glial cells promotes remyelination in models of multiple sclerosis (MS).
Within this set, the mouse antibody, SCH94.03, was immunomodulatory implying that immune system mobilization might be integral to remyelination.
We evaluated whether the human remyelination-promoting antibody rHIgM22 influences acquired immunity.
The antibody did not bind to immune cells, or influence humoral immune responses, antigen presentation, T cell proliferation or cytokine production.
Treatment with rHIgM22 had no effect on demyelination or virus infection in two disease models.
These results demonstrate that the remyelination-promoting activity of antibody rHIgM22 is not dependent on immunomodulation.